Clinicopathologic features of 56 EDs in patients with newly diagnosed APL
| Clinicopathologic parameter . | Value . |
|---|---|
| Period of diagnosis | |
| 2007-2012 | 30 (53.6) |
| 2013-2020 | 26 (46.4) |
| Sex | |
| Male | 35 (62.5) |
| Female | 21 (37.5) |
| Median age (range), y | 54.5 (1-97) |
| Age ≥50 years | 36 (64.3) |
| Age groups, y | |
| ≤17 | 5 (8.9) |
| 18-29 | 4 (7.1) |
| 30-39 | 5 (8.9) |
| 40-49 | 6 (10.7) |
| 50-59 | 16 (28.6) |
| 60-69 | 13 (23.2) |
| ≥70 | 7 (12.5) |
| Institution at initial presentation | |
| Regional hospitals | 52 (92.9) |
| QMH | 4 (7.1) |
| Hematologic features at presentation | |
| Hemoglobin, median (range), g/dL | 8 (3.9-14.8) |
| Hemoglobin <8 g/dL | 28 (50) |
| Leucocyte count, median (range), ×109/L | 15.8 (0.9-337.6) |
| Leucocyte count, ≥10 × 109/L | 33 (58.9) |
| Platelet count, median (range), ×109/L | 22 (4-168) |
| Platelet count <40 × 109/L | 41 (73.2) |
| PT, median (range), s* | 16.2 (11.5-65.5) |
| PT ≥16 s* | 30 (53.6) |
| Activated partial thromboplastin time, median (range), s* | 30.3 (21.4-47.2) |
| Activated partial thromboplastin time ≥40 s* | 5 (8.9) |
| Fibrinogen, median (range), g/L* | 1.1 (0.3-6.0) |
| Fibrinogen <1.5 g/L* | 35 (62.5) |
| Time from admission to first dose of ATRA, median (range), h | 24 (6-192) |
| Timing of ATRA administration | |
| 0-24 h of presentation | 35 (62.5) |
| >24 h after presentation | 21 (37.5) |
| Deaths within 30 d of presentation | |
| 0-2 d | 11 (19.6) |
| 3-7 d | 22 (39.3) |
| 8-30 d | 23 (41.2) |
| Cause of death within 30 d of presentation | |
| ICH | 25 (44.6) |
| Complications from APL-DS | 23 (41.1) |
| Infections | 8 (14.3) |
| Clinicopathologic parameter . | Value . |
|---|---|
| Period of diagnosis | |
| 2007-2012 | 30 (53.6) |
| 2013-2020 | 26 (46.4) |
| Sex | |
| Male | 35 (62.5) |
| Female | 21 (37.5) |
| Median age (range), y | 54.5 (1-97) |
| Age ≥50 years | 36 (64.3) |
| Age groups, y | |
| ≤17 | 5 (8.9) |
| 18-29 | 4 (7.1) |
| 30-39 | 5 (8.9) |
| 40-49 | 6 (10.7) |
| 50-59 | 16 (28.6) |
| 60-69 | 13 (23.2) |
| ≥70 | 7 (12.5) |
| Institution at initial presentation | |
| Regional hospitals | 52 (92.9) |
| QMH | 4 (7.1) |
| Hematologic features at presentation | |
| Hemoglobin, median (range), g/dL | 8 (3.9-14.8) |
| Hemoglobin <8 g/dL | 28 (50) |
| Leucocyte count, median (range), ×109/L | 15.8 (0.9-337.6) |
| Leucocyte count, ≥10 × 109/L | 33 (58.9) |
| Platelet count, median (range), ×109/L | 22 (4-168) |
| Platelet count <40 × 109/L | 41 (73.2) |
| PT, median (range), s* | 16.2 (11.5-65.5) |
| PT ≥16 s* | 30 (53.6) |
| Activated partial thromboplastin time, median (range), s* | 30.3 (21.4-47.2) |
| Activated partial thromboplastin time ≥40 s* | 5 (8.9) |
| Fibrinogen, median (range), g/L* | 1.1 (0.3-6.0) |
| Fibrinogen <1.5 g/L* | 35 (62.5) |
| Time from admission to first dose of ATRA, median (range), h | 24 (6-192) |
| Timing of ATRA administration | |
| 0-24 h of presentation | 35 (62.5) |
| >24 h after presentation | 21 (37.5) |
| Deaths within 30 d of presentation | |
| 0-2 d | 11 (19.6) |
| 3-7 d | 22 (39.3) |
| 8-30 d | 23 (41.2) |
| Cause of death within 30 d of presentation | |
| ICH | 25 (44.6) |
| Complications from APL-DS | 23 (41.1) |
| Infections | 8 (14.3) |
55 patients and 49 patients had clotting profile and fibrinogen level tested at presentation, respectively.